AptaBio Therapeutics

About AptaBio Therapeutics

AptaBio Therapeutics is a South Korean biopharmaceutical company established in 2009, specializing in the development of 'first-in-class' drugs for intractable diseases. The company's name, 'Apta', is derived from the Greek word for 'to fit well', reflecting its goal of creating precisely targeted medications for patients.

The firm's research and development is centered on three core platform technologies. The 'Oxidative Stress Modulation' platform targets the root causes of inflammation and fibrosis to develop treatments for diabetic complications, vascular diseases, and neurodegenerative disorders. Its 'Apta-DC (Aptamer-Drug Conjugate)' platform is engineered to create anticancer drugs that overcome resistance and reduce side effects, targeting proteins that are difficult to address with small molecules. The third platform focuses on regulating 'Cancer-Associated Fibroblasts (CAF)' to enhance the effectiveness of immuno-oncology therapies.

AptaBio's pipeline includes several drug candidates at various stages of clinical development. A key candidate, Isuzinaxib (APX-115), is a pan-NOX inhibitor being developed for diabetic kidney disease and contrast-induced acute kidney injury. The company is also advancing treatments for MASH (formerly NASH), macular degeneration, and Parkinson's disease. In oncology, AptaBio is developing treatments for solid tumors and blood cancers like acute myeloid leukemia (AML), with its Apta-16 candidate receiving orphan drug designation from the FDA.

The company operates in the global biopharmaceutical market, aiming to address significant unmet medical needs through licensing out its technologies and co-development partnerships. AptaBio is a public company listed on the KRX exchange.